Key Points
- Insider sale: Christopher Heery sold 6,131 Arcellx shares on January 12 for a total of $393,303.65 (avg $64.15), cutting his holdings by 14.19% to 37,068 shares (≈$2.38M).
- Arcellx reported a quarterly loss (EPS -$0.99) and revenue of $4.95M that missed estimates, with deeply negative net margin and return on equity, highlighting continued operating losses.
- Market context: ACLX trades around $64.87 with a 52‑week range of $47.86–$94.07, about 96% institutional ownership, and an average analyst price target of $112.22 (consensus "Moderate Buy").
Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 6,131 shares of Arcellx stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $64.15, for a total value of $393,303.65. Following the sale, the insider directly owned 37,068 shares of the company's stock, valued at approximately $2,377,912.20. The trade was a 14.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Christopher Heery also recently made the following trade(s):
- On Monday, November 17th, Christopher Heery sold 340 shares of Arcellx stock. The shares were sold at an average price of $90.00, for a total value of $30,600.00.
Arcellx Price Performance
ACLX stock opened at $64.87 on Tuesday. Arcellx, Inc. has a fifty-two week low of $47.86 and a fifty-two week high of $94.07. The stock has a market capitalization of $3.75 billion, a price-to-earnings ratio of -16.51 and a beta of 0.36. The business's fifty day moving average price is $73.69 and its two-hundred day moving average price is $74.88.
Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.03). Arcellx had a negative net margin of 607.01% and a negative return on equity of 51.13%. The business had revenue of $4.95 million during the quarter, compared to analyst estimates of $11.24 million. Research analysts expect that Arcellx, Inc. will post -1.58 EPS for the current year.
Institutional Trading of Arcellx
Institutional investors and hedge funds have recently modified their holdings of the business. MAI Capital Management bought a new position in Arcellx in the third quarter valued at about $26,000. CWM LLC boosted its stake in shares of Arcellx by 267.0% in the 3rd quarter. CWM LLC now owns 345 shares of the company's stock valued at $28,000 after purchasing an additional 251 shares in the last quarter. State of Wyoming bought a new stake in shares of Arcellx during the 2nd quarter valued at approximately $28,000. Ramirez Asset Management Inc. acquired a new position in Arcellx during the 3rd quarter worth approximately $41,000. Finally, Abich Financial Wealth Management LLC bought a new position in Arcellx in the 3rd quarter valued at approximately $62,000. 96.03% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ACLX. Guggenheim reiterated a "buy" rating on shares of Arcellx in a research report on Monday, November 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Arcellx in a research note on Wednesday, October 8th. Cantor Fitzgerald reiterated a "neutral" rating and set a $88.00 target price on shares of Arcellx in a research report on Thursday, October 9th. Citigroup restated a "buy" rating on shares of Arcellx in a research report on Monday, November 24th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $105.00 price target on shares of Arcellx in a research note on Monday, December 8th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $112.22.
Check Out Our Latest Stock Report on ACLX
About Arcellx
(
Get Free Report)
Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.
The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
